All In MedTech

Device Trial Radar · NCT03332238

Stromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears

A Phase II Study to Evaluate Autologous Stromal Vascular Fraction Cell Therapy to Improve the Repair of Chronically Rotator Cuff Tears

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Jul 1, 2019

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Hospital for Special Surgery, New YorkAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Orthopedic Research and Education Foundation
First posted
Nov 6, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 45 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rotator cuff disease is one of the most prevalent musculoskeletal conditions across the world. Patients with chronic rotator cuff tears often have substantial muscle atrophy and fatty infiltration. Surgical repair of the tear does not reverse the atrophy, and many patients continue to experience weakness, pain, and a persistent reduction in the quality of life. An important limitation in our ability to successfully rehabilitate these injuries postoperatively and return patients to normal function has to do with the poor quality of the muscle and tendon after rotator cuff repair. The stromal vascular fraction (SVF) of subcutaneous adipose tissue is highly enriched with cells (SVFCs) that can both directly participate in tissue regeneration by differentiating into myogenic and tenogenic cells, and indirectly by secreting growth factors and small molecules which activate pathways associated with healthy tissue regeneration. High numbers of autologous SVFCs can be isolated using the cost-effective, intraoperative Icellator (Tissue Genesis, Honolulu, HI) point-of-care system. This clinical trial will be determine if the use of SVFCs can enhance outcomes for patients who are undergoing surgical repair of a torn supraspinatus rotator cuff.

Conditions

  • Rotator Cuff Tear
  • Muscle Atrophy
  • Tendon Tear

Interventions

  • Autologous Stomal Vascular Fraction MaterialDevice

    Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™

  • Ringer's solutionDevice

    Ringer's solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in scapular plane abduction strength from baseline, and additional isometric, isokinetic strength measurements to assess supraspinatus function.Time frame: 2 weeks prior to surgery, 6 months after surgery, 12 months after surgery, 24 months after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital for Special Surgery

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.